Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(1.03)
# 3,763
Out of 4,918 analysts
10
Total ratings
62.5%
Success rate
-10.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $2.08 | +284.62% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $20.03 | +24.81% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $6.56 | +616.46% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $2.00 | +150.00% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $24.67 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $2.99 | +635.79% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $22.95 | +396.73% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $11.95 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.08
Upside: +284.62%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $20.03
Upside: +24.81%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $6.56
Upside: +616.46%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $2.00
Upside: +150.00%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $24.67
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $2.99
Upside: +635.79%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $22.95
Upside: +396.73%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $11.95
Upside: -